MNPR
Price
$82.82
Change
+$2.22 (+2.75%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
538.62M
Intraday BUY SELL Signals
XNCR
Price
$15.77
Change
-$0.25 (-1.56%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
1.14B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MNPR vs XNCR

Header iconMNPR vs XNCR Comparison
Open Charts MNPR vs XNCRBanner chart's image
Monopar Therapeutics
Price$82.82
Change+$2.22 (+2.75%)
Volume$1.27K
Capitalization538.62M
Xencor
Price$15.77
Change-$0.25 (-1.56%)
Volume$22.81K
Capitalization1.14B
MNPR vs XNCR Comparison Chart in %
MNPR
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MNPR vs. XNCR commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a Hold and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (MNPR: $80.60 vs. XNCR: $16.03)
Brand notoriety: MNPR and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 155% vs. XNCR: 98%
Market capitalization -- MNPR: $554.65M vs. XNCR: $1.13B
MNPR [@Biotechnology] is valued at $554.65M. XNCR’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • MNPR’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, MNPR is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • MNPR’s TA Score: 5 bullish, 4 bearish.
  • XNCR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MNPR and XNCR are a good buy in the short-term.

Price Growth

MNPR (@Biotechnology) experienced а -3.39% price change this week, while XNCR (@Biotechnology) price change was +7.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

XNCR is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($1.15B) has a higher market cap than MNPR($539M). MNPR YTD gains are higher at: 266.364 vs. XNCR (-30.244). MNPR has higher annual earnings (EBITDA): -19.11M vs. XNCR (-125.38M). XNCR has more cash in the bank: 444M vs. MNPR (53.3M). MNPR has less debt than XNCR: MNPR (80.4K) vs XNCR (67.9M). XNCR has higher revenues than MNPR: XNCR (147M) vs MNPR (0).
MNPRXNCRMNPR / XNCR
Capitalization539M1.15B47%
EBITDA-19.11M-125.38M15%
Gain YTD266.364-30.244-881%
P/E RatioN/AN/A-
Revenue0147M-
Total Cash53.3M444M12%
Total Debt80.4K67.9M0%
FUNDAMENTALS RATINGS
MNPR vs XNCR: Fundamental Ratings
MNPR
XNCR
OUTLOOK RATING
1..100
7471
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
85
Overvalued
PROFIT vs RISK RATING
1..100
42100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNPR's Valuation (31) in the null industry is somewhat better than the same rating for XNCR (85) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than XNCR’s over the last 12 months.

MNPR's Profit vs Risk Rating (42) in the null industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's SMR Rating (95) in the Biotechnology industry is in the same range as MNPR (96) in the null industry. This means that XNCR’s stock grew similarly to MNPR’s over the last 12 months.

MNPR's Price Growth Rating (35) in the null industry is in the same range as XNCR (37) in the Biotechnology industry. This means that MNPR’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for MNPR (100) in the null industry. This means that XNCR’s stock grew significantly faster than MNPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNPRXNCR
RSI
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
63%
MACD
ODDS (%)
Bearish Trend 7 days ago
88%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
MNPR
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BTBFX65.43N/A
N/A
Boston Trust Asset Management
PRJCX41.21N/A
N/A
PGIM Jennison Global Opportunities C
ACWEX17.41N/A
N/A
Cavanal Hill World Energy C
LHCSX22.38N/A
N/A
Lord Abbett Health Care R4
SGDLX108.72N/A
N/A
Sprott Gold Equity Investor

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+5.46%
QNCX - MNPR
36%
Loosely correlated
+6.67%
ROIV - MNPR
31%
Poorly correlated
-0.17%
IDYA - MNPR
30%
Poorly correlated
+1.08%
XNCR - MNPR
30%
Poorly correlated
+2.62%
AVTX - MNPR
29%
Poorly correlated
+6.67%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with NUVL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+2.62%
NUVL - XNCR
60%
Loosely correlated
-3.48%
CRNX - XNCR
60%
Loosely correlated
-1.17%
IDYA - XNCR
55%
Loosely correlated
+1.08%
NRIX - XNCR
55%
Loosely correlated
-1.02%
RCUS - XNCR
54%
Loosely correlated
+1.00%
More